Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

Supply for Vabysmo PFS will become available to Canadian ophthalmologists and their patients in the coming months. Roche Canada is committed to continuing to work with the provincial and ...

Support for measurement units in R vectors, matrices and arrays: automatic propagation, conversion, derivation and simplification of units; raising errors in case of unit incompatibility. Compatible ...

Xoma earns a 0.5% royalty on Vabysmo, and the consensus projections indicate substantial sales growth from $5.0 billion in 2025 to $7.9 billion by 2030, translating into royalties of $25 million ...

But we didn’t have all the tools necessary to optimize Eylea HD.” Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise The ...

The number is “likely to raise questions” about the drug’s long-term competitiveness against Roche’s Vabysmo, Kasimov added. The analyst expects questions to persist around the company’s ...

However, Eylea’s sales have been under pressure in the last couple of years due to competition from Roche’s RHHBY Vabysmo. The uptake of Roche’s Vabysmo has been phenomenal. Roche has ...